FDA/CDC

Polycythemia vera test detects JAK2 V617F/G1849T mutation


 

The ipsogen JAK2 RGQ PCR Kit has been given marketing authorization by the Food and Drug Administration.

This is the first FDA-authorized test for use in evaluating patients for suspected polycythemia vera, according to an FDA press release. Manufactured by Qiagen, the kit detects the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole blood.

The presence of JAK2 mutations is one of the major criteria for clinical confirmation of polycythemia vera. The V617F/G1849T mutation is detected in more than 94% of these patients. This test does not detect less common mutations including mutations in exon 12 and is not intended for stand-alone diagnosis, which is based on other clinicopathological factors of polycythemia vera.

Marketing authorization, granted March 27, 2017, was based on data from a clinical study of 216 patients with suspected polycythemia vera. The study compared results from the ipsogen JAK2 RGQ PCR Kit with results obtained with Sanger sequencing. In the study, the ipsogen JAK2 RGQ PCR Kit test detected polycythemia vera with 94.6% sensitivity and 98.1% specificity.

Further information about the JAK2 RGQ PCR Kit is available at https://www.accessdata.fda.gov/cdrh_docs/pdf16/DEN160028.pdf.

On Twitter @maryjodales

Recommended Reading

MDS gene mutations predict response to HSCT
MDedge Hematology and Oncology
NCCN: Myelofibrosis guideline is first in series on MPNs
MDedge Hematology and Oncology
NCCN myelofibrosis guideline: Patient voice is key
MDedge Hematology and Oncology
Myelofibrosis therapies moving beyond ruxolitinib
MDedge Hematology and Oncology
Protein may prevent transformation from MDS to AML
MDedge Hematology and Oncology
FDA grants mAb orphan designation for MDS
MDedge Hematology and Oncology
Model illustrates progression to MDS, AML
MDedge Hematology and Oncology
Genetic profiling can guide HSCT in MDS, team says
MDedge Hematology and Oncology
Azathioprine may increase risk of MDS, AML
MDedge Hematology and Oncology
Targeting disease stem cells in AML, MDS
MDedge Hematology and Oncology